Harrow Initiates Phase 3 Trial for TRIESENCE Label Expansion in Post-Cataract Surgery Care
HROW has more than doubled off its 52-week low of $20.85.
Summary
Harrow, Inc. has initiated a Phase 3 clinical trial for its TRIESENCE product, seeking to expand its label to include ocular inflammation and pain following cataract surgery. The FDA has cleared the Investigational New Drug (IND) application for this randomized, placebo-controlled study. This development follows the company's recent strong financial performance, including a Q4 revenue beat and positive 2025 results, and aligns with its growth strategy. The expansion targets a significant market, with over 4 million cataract surgeries performed annually in the U.S., potentially addressing a key patient compliance challenge with post-operative eye drops. A successful trial and label expansion could materially enhance TRIESENCE's commercial profile and future revenue streams for Harrow. Investors will now monitor the progress and eventual results of this pivotal trial.
At the time of this announcement, HROW was trading at $45.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $20.85 to $54.85. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.